What does the research say about Detectable MDS hematopoietic stem cells?

Detectable MDS hematopoietic stem cells

There is 1 paper on detectable MDS hematopoietic stem cells in aging research: 1 observational study in people. The newest story, Oct 29, 2026: “Stem-cell mutations predicted blood cancer relapse after transplant”.

Biomarker

1 paper studies it1 finding

1 new paper in 30 daysSee all 1

Humans1

Interventions

Venetoclax + azacitidine

downin humans1

1 study

Venetoclax + azacitidine is linked with lower detectable MDS hematopoietic stem cells in humans (patients with myelodysplastic neoplasms evaluated longitudinally).
“Venetoclax/azacytidine depleted detectable MDS HSCs in longitudinally evaluated patients.”
Humanspatients with myelodysplastic neoplasms evaluated longitudinallyhematopoietic stem cell
Stem-cell mutations predicted blood cancer relapse after transplant
bioRxivOct 29, 2026Preprint

Latest

1 paper in 12 months

bioRxivOct 29

Stem-cell mutations predicted blood cancer relapse after transplant

Relapse was reported in 95.7% of patients with detected stem-cell mutations versus 30.3% without them in an observational cohort after transplantation.Relapse was reported in 95.7% of patients with detected stem-cell mutations versus 30.3% without them in an observational cohort after transplantation.

Preprint: cohort studyBiomarkers

Paper

Detectable MDS hematopoietic stem cells

Interventions

Latest

Stem-cell mutations predicted blood cancer relapse after transplant

Related